Biomea Fusion Inc (US: BMEA) — Healthcare · Share Price, Chart & Market Data
About: Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.45 (-5.23%)
BMEABiomea Fusion Inc
Loading watchlist status…
Trade BMEA now
Biomea Fusion Inc share price
BMEA price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
30 Apr, 6:38 am GMT+0
BMEA price performance
-22.46%
5D
9.848%
1M
8.209%
YTD
-34.091%
1Y
BMEA price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US rank
N/A
Sector Rank
N/A
Delayed
30 Apr, 6:38 am GMT+0
BMEA details
BMEA Market Signals